HSP90AA1 and autoimmune disease: On the other hand, numerous preclinical studies using Hsp90 inhibitors, with N-terminal affinity, seem to be promising for the treatment of inflammatory/autoimmune diseases due to the activation of an HRS and attenuation of various pro-inflammatory molecules (Tukaj and Węgrzyn 2016; Tukaj and Sitko 2022).